Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 4/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20912266 | 0.91 | SRC (0.59) | SRCMAPTLMNAKMT2AHTT | |
| SCHEMBL22604421 | 0.87 | SRC (0.67) | SRCMAPTLMNAKMT2AHTT | |
| SCHEMBL20911666 | 0.85 | SRC (0.66) | SRCMAPTLMNAKMT2AHTT | |
| SCHEMBL20912264 | 0.81 | SRC (0.58) | SRCMAPTLMNAKMT2AHTT | |
| SCHEMBL20912342 | 0.80 | PARP1 (0.37) | SRCMAPTLMNAKMT2AHPGDS | |
| SCHEMBL20911676 | 0.78 | SRC (0.67) | SRCMAPTLMNAKMT2AHTT | |
| SCHEMBL20912120 | 0.78 | SRC (0.61) | SRCMAPTLMNAKMT2AHTT | |
| SCHEMBL22604454 | 0.78 | MAP4K4 (0.42) | SRCMAPTLMNAKMT2AHTT | |
| SCHEMBL20911667 | 0.77 | SRC (0.69) | SRCMAPTLMNAKMT2AHTT | |
| SCHEMBL27195247 | 0.77 | SRC (0.79) | SRCMAPTLMNAKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-20200339583-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339583-A1 | MAP4K4 INHIBITORS | MAP4K4, MAP4K2, MAP4K5 | SRC 594/4885MAPT 315/4885LMNA 4334/4885 |
| US-11795169-B2 | MAP4K4 inhibitors | MAP4K4, MAP4K2, MAP4K5 | SRC 594/4885MAPT 315/4885LMNA 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.